Diet-induced obesity exacerbates metabolic and behavioral effects of polycystic ovary syndrome in a rodent model

American Journal of Physiology - Endocrinology and Metabolism

Volumn 308, Issue 12, 2015, Pages E1076-E1084

  Ressler, Ilana B ^a,b   Grayson, Bernadette E ^c   Ulrich Lai, Yvonne M ^d   Seeley, Randy J ^e  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Anxiety; Depression; Lean; Obesity; Polycystic ovary syndrome

Indexed keywords

ANDROSTANOLONE; CHOLESTEROL; CORTICOSTERONE; INTERLEUKIN 1BETA; PLACEBO; PROTEIN C FOS; SATURATED FATTY ACID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARCUATE NUCLEUS; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEPRESSION; DIET INDUCED OBESITY; DISEASE EXACERBATION; ELEVATED PLUS MAZE TEST; FAT INTAKE; FAT MASS; FEMALE; FORCED SWIM TEST; HYPERANDROGENISM; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; IMMOBILITY; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LOW FAT DIET; METABOLIC STRESS; NONHUMAN; ORGAN WEIGHT; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RAT; RODENT MODEL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; ZONA INCERTA; ADVERSE EFFECTS; ANIMAL; ANIMAL BEHAVIOR; CALORIC INTAKE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GLUCOSE INTOLERANCE; LIPID DIET; LONG EVANS RAT; MENTAL STRESS; METABOLISM; OBESITY; PHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; PSYCHOLOGY;

ADIPOSITY; ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; DIET, HIGH-FAT; DIHYDROTESTOSTERONE; DISEASE MODELS, ANIMAL; ENERGY INTAKE; FEMALE; GLUCOSE INTOLERANCE; INSULIN RESISTANCE; OBESITY; POLYCYSTIC OVARY SYNDROME; RATS; RATS, LONG-EVANS; STRESS, PSYCHOLOGICAL;

EID: 84931051690     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00182.2014     Document Type: Article

References (58)

1. Andersen P, Seljeflot I, Abdelnoor M, Arnesen H, Dale PO, Lovik A, Birkeland K. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 44: 611–616, 1995.
2. Anttila L, Koskinen P, Jaatinen TA, Erkkola R, Irjala K, Ruutiainen K. Insulin hypersecretion together with high luteinizing hormone concentration augments androgen secretion in oral glucose tolerance test in women with polycystic ovarian disease. Hum Reprod 8: 1179–1183, 1993.
3. Arroyo A, Laughlin GA, Morales AJ, Yen SS. Inappropriate gonado-tropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab 82: 3728–3733, 1997.
4. Bates GW, Whitworth NS. Effect of body weight reduction on plasma androgens in obese, infertile women. Fertil Steril 38: 406–409, 1982.
5. Becker JB, Arnold AP, Berkley KJ, Blaustein JD, Eckel LA, Hampson E, Herman JP, Marts S, Sadee W, Steiner M, Taylor J, Young E. Strategies and methods for research on sex differences in brain and behavior. Endocrinology 146: 1650–1673, 2005.
6. Benson S, Arck PC, Tan S, Hahn S, Mann K, Rifaie N, Janssen OE, Schedlowski M, Elsenbruch S. Disturbed stress responses in women with polycystic ovary syndrome. Psychoneuroendocrinology 34: 727–735, 2009.
7. Blank SK, McCartney CR, Marshall JC. The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Hum Reprod Update 12: 351–361, 2006.
8. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandro-genism with hyperinsulinism in polycystic ovarian disease. J Clin Endo-crinol Metab 50: 113–116, 1980.
9. Caldwell AS, Middleton LJ, Jimenez M, Desai R, McMahon AC, Allan CM, Handelsman DJ, Walters KA. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models. Endocrinology 155: 3146–3159, 2014.
10. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 57: 356–359, 1983.
11. Ching HL, Burke V, Stuckey BG. Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers. Clin Endocrinol (Oxf) 66: 373–379, 2007.
12. Crave JC, Fimbel S, Lejeune H, Cugnardey N, Dechaud H, Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 80: 2057–2062, 1995.
13. Cryan JF, Page ME, Lucki I. Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl) 182: 335–344, 2005.
14. Dale PO, Tanbo T, Vaaler S, Abyholm T. Body weight, hyperinsulin-emia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations. Fertil Steril 58: 487–491, 1992.
15. de Franca Neto AH, Rogatto S, Do Amorim MM, Tamanaha S, Aoki T, Aldrighi JM. Oncological repercussions of polycystic ovary syndrome. Gynecol Endocrinol 26: 708–711, 2010.
16. Diamanti-Kandarakis E, Panidis D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol (Oxf) 67: 735–742, 2007.
17. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38: 1165–1174, 1989.
18. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22: 141–146, 1999.
19. Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab 90: 66–71, 2005.
20. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 97: 28–38.e25, 2012.
21. Feng Y, Johansson J, Shao R, Manneras L, Fernandez-Rodriguez J, Billig H, Stener-Victorin E. Hypothalamic neuroendocrine functions in rats with dihydrotestosterone-induced polycystic ovary syndrome: effects of low-frequency electro-acupuncture. PLoS One 4: e6638, 2009.
22. Gallinelli A, Matteo ML, Volpe A, Facchinetti F. Autonomic and neuroendocrine responses to stress in patients with functional hypotha-lamic secondary amenorrhea. Fertil Steril 73: 812–816, 2000.
23. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 26: 883–896, 2002.
24. Glueck CJ, Dharashivkar S, Wang P, Zhu B, Gartside PS, Tracy T, Sieve L. Obesity and extreme obesity, manifest by ages 20–24 years, continuing through 32–41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy. Eur J Obstet Gynecol Reprod Biol 122: 206–212, 2005.
25. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 80: 2586–2593, 1995.
26. Holte J, Bergh T, Gennarelli G, Wide L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of go-nadotrophins and sex steroids in premenopausal women. Clin Endocrinol (Oxf) 41: 473–481, 1994.
27. Jedel E, Gustafson D, Waern M, Sverrisdottir YB, Landen M, Janson PO, Labrie F, Ohlsson C, Stener-Victorin E. Sex steroids, insulin sensitivity and sympathetic nerve activity in relation to affective symptoms in women with polycystic ovary syndrome. Psychoneuroendocrinol-ogy 36: 1470–1479, 2011.
28. Jedel E, Waern M, Gustafson D, Landen M, Eriksson E, Holm G, Nilsson L, Lind AK, Janson PO, Stener-Victorin E. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Hum Reprod 25: 450–456, 2010.
29. Kerchner A, Lester W, Stuart SP, Dokras A. Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study. Fertil Steril 91: 207–212, 2009.
30. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Franks S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 36: 105–111, 1992.
31. Kiddy DS, Sharp PS, White DM, Scanlon MF, Mason HD, Bray CS, Polson DW, Reed MJ, Franks S. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf) 32: 213–220, 1990.
32. Kopelman PG, White N, Pilkington TR, Jeffcoate SL. The effect of weight loss on sex steroid secretion and binding in massively obese women. Clin Endocrinol (Oxf) 15: 113–116, 1981.
33. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84: 165–169, 1999.
34. Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG 113: 1203–1209, 2006.
35. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG. Overweight, obesity, and depression: A systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 67: 220–229, 2010.
36. Luque-Ramírez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF. Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum Reprod 22: 3197–3203, 2007.
37. Manneras L, Cajander S, Holmang A, Seleskovic Z, Lystig T, Lonn M, Stener-Victorin E A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology 148: 3781–3791, 2007.
38. Manneras L, Jonsdottir IH, Holmang A, Lonn M, Stener-Victorin E. Low-frequency electro-acupuncture and physical exercise improve metabolic disturbances and modulate gene expression in adipose tissue in rats with dihydrotestosterone-induced polycystic ovary syndrome. Endocrinology 149: 3559–3568, 2008.
39. Mansson M, Holte J, Landin-Wilhelmsen K, Dahlgren E, Johansson A, Landen M. Women with polycystic ovary syndrome are often depressed or anxious—a case control study. Psychoneuroendocrinology 33: 1132–1138, 2008.
40. Maranon RO, Lima R, Spradley FT, do Carmo JM, Zhang H, Smith A, Bui E, Thomas L, Moulana M, Hall JE, Granger JP, Reckelhoff JF. Roles for the sympathetic nervous system, renal nerves, and CNS mela-nocortin-4 receptor in the elevated blood pressure in hyperandrogenemic female rats. Am J Physiol Regul Integr Comp Physiol 308: R708–R713, 2015.
41. McCook JG, Bailey BA, Williams SL, Anand S, Reame NE. Differential Contributions of Polycystic Ovary Syndrome (PCOS) Manifestations to Psychological Symptoms. J Behav Health Serv Res. In press.
42. Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 81: 2854–2864, 1996.
43. Munzker J, Hofer D, Trummer C, Ulbing M, Harger A, Pieber T, Owen L, Keevil B, Brabant G, Lerchbaum E, Obermayer-Pietsch B. Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome. J Clin Endocrinol Metab 100: 653–660, 2015.
44. Nestler JE, Clore JN, Blackard WG. The central role of obesity (hyperinsulinemia) in the pathogenesis of the polycystic ovary syndrome. Am J Obstet Gynecol 161: 1095–1097, 1989.
45. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 83: 2001–2005, 1998.
46. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. San Diego, CA: Academic, 1998.
47. Ressler IB, Grayson BE, Seeley RJ. Metabolic, behavioral, and reproductive effects of vertical sleeve gastrectomy in an obese rat model of polycystic ovary syndrome. Obes Surg 24: 866–876, 2014.
48. Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, Teede HJ. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod 28: 777–784, 2013.
49. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, Kuller LH. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 20: 2414–2421, 2000.
50. Teede HJ, Hutchison SK, Zoungas S. The management of insulin resistance in polycystic ovary syndrome. Trends Endocrinol Metab 18: 273–279, 2007.
51. Ulrich-Lai YM, Arnhold MM, Engeland WC. Adrenal splanchnic innervation contributes to the diurnal rhythm of plasma corticosterone in rats by modulating adrenal sensitivity to ACTH. Am J Physiol Regul Integr Comp Physiol 290: R1128–R1135, 2006.
52. Ulrich-Lai YM, Ostrander MM, Thomas IM, Packard BA, Furay AR, Dolgas CM, Van Hooren DC, Figueiredo HF, Mueller NK, Choi DC, Herman JP. Daily limited access to sweetened drink attenuates hypotha-lamic-pituitary-adrenocortical axis stress responses. Endocrinology 148: 1823–1834, 2007.
53. Vahl TP, Ulrich-Lai YM, Ostrander MM, Dolgas CM, Elfers EE, Seeley RJ, D’Alessio DA, Herman JP. Comparative analysis of ACTH and corticosterone sampling methods in rats. Am J Physiol Endocrinol Metab 289: E823–E828, 2005.
54. van Houten EL, Kramer P, McLuskey A, Karels B, Themmen AP, Visser JA. Reproductive and metabolic phenotype of a mouse model of PCOS. Endocrinology 153: 2861–2869, 2012.
55. Weiner CL, Primeau M, Ehrmann DA. Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med 66: 356–362, 2004.
56. Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 95: 1073–1079.e1–11, 2011.
57. Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 3: 101–105, 2000.
58. Zhao G, Ford ES, Li C, Tsai J, Dhingra S, Balluz LS. Waist circumference, abdominal obesity, and depression among overweight and obese U.S. adults: National Health and Nutrition Examination Survey 2005– 2006. BMC Psychiatry 11: 130, 2011.